ESC 365 - Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

ESC Premium Access

Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

Session: Safety issues with anti-platelets drugs

Topic: Antiplatelet Drugs

Speaker: Associate Professor V. Serebruany (Baltimore, US)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Associate Professor Victor L Serebruany

Johns Hopkins University of Baltimore, Baltimore (United States of America)

2 presentations

0 follower

3 more presentations in this session

Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-pci prospective registry

Speaker: Doctor M. Ferlini (Pavia, IT)

Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?

Speaker: Doctor M. Ferlini (Pavia, IT)

Platelet inhibition on brand and generic clopidogrel chronic therapy

Speaker: Doctor A. Soliman (Dammam, SA)

Access the full session

Safety issues with anti-platelets drugs

Speakers: Associate Professor V. Serebruany, Doctor M. Ferlini, Doctor M. Ferlini, Doctor A. Soliman

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources